The effect of esketamine on gastrointestinal function after gynecological laparoscopic surgery: a randomized, double-blind, controlled study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052528

Enrollment

Unknown

Registered

2021-10-30

Start date

2022-04-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological Laparoscopic Surgery

Interventions

control group:Standard opioid-based anesthesia regimens

experimental group:Esketamine anesthesia program

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 65 years; 2. ASA I-II; 3. Underwent laparoscopic gynecological surgery (hysterectomy, ovarian cystectomy, bilateral adnexectomy); 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Emergency surgery; 3. Adults protected by law (under judicial protection, guardianship or supervision), persons deprived of their liberty; 4. Atrioventricular block, sinus node block, or intraventricular block; 5. Sinus bradycardia (basic heart rate is less than 60 beats/min); 6. Preoperative hypotension (systolic blood pressure less than 100mmHg); 7. Preoperative otolithiasis, Meniere syndrome, vertebral artery stenosis; 8. Cerebrovascular disease; 9. NSAIDs drug contraindications; 10. Allergic to narcotic drugs.

Design outcomes

Primary

Measure	Time frame
First exhaust time after operation;	—

Secondary

Measure	Time frame
Intraoperative remifentanil dosage;Sufentanil dosage during surgery;Probability of intraoperative cardiovascular complications;Preoperative Self-Rating Depression Scale Test;Basic conditions during the operation (blood pressure, heart rate, body temperature);Intraoperative vasoactive drug dosage (ephedrine, phenylephrine, atropine, esmolol, etc.);Intraoperative fluid volume, bleeding volume, urine volume;Intraoperative complications (arrhythmia, myocardial infarction, cardiac arrest, hypoxemia, allergies, intraoperative awareness, etc.);Time from extubation to Aldrete greater than 9 minutes;NRS score;Remedial analgesia;Nausea and vomiting;Dizziness;Dosage of opioids at 24h and 48h after operation;24h postoperative depression self-rating scale test (SDS);Probability of postoperative cardiovascular complications;Postoperative hospital stay;	—

Measure

Time frame

Intraoperative remifentanil dosage;Sufentanil dosage during surgery;Probability of intraoperative cardiovascular complications;Preoperative Self-Rating Depression Scale Test;Basic conditions during the operation (blood pressure, heart rate, body temperature);Intraoperative vasoactive drug dosage (ephedrine, phenylephrine, atropine, esmolol, etc.);Intraoperative fluid volume, bleeding volume, urine volume;Intraoperative complications (arrhythmia, myocardial infarction, cardiac arrest, hypoxemia, allergies, intraoperative awareness, etc.);Time from extubation to Aldrete greater than 9 minutes;NRS score;Remedial analgesia;Nausea and vomiting;Dizziness;Dosage of opioids at 24h and 48h after operation;24h postoperative depression self-rating scale test (SDS);Probability of postoperative cardiovascular complications;Postoperative hospital stay;

—

Countries

China

Contacts

Public ContactMa Yuhua

People's Hospital of Xing'an League, Inner Mongolia

mayuhua0665@163.com+86 13847930665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026